# HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

> **NCT05553639** · PHASE1,PHASE2 · TERMINATED · sponsor: **Hookipa Biotech GmbH** · enrollment: 12 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **BIOLOGICAL:** HB-302/HB-301 Alternating 2-Vector Therapy

## Key facts

- **NCT ID:** NCT05553639
- **Lead sponsor:** Hookipa Biotech GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-05-23
- **Primary completion:** 2024-04-29
- **Final completion:** 2024-04-29
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Decision by the company to terminate the H-300-001 study early for non-safety related reasons.
- **Last updated:** 2024-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05553639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05553639, "HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT05553639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*